
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate Inc. operates in a growing market, with total ADHD medication sales in the U.S. increasing approximately 8% annually since 2010, reaching around $18 billion in 2020, indicating robust demand for ADHD treatments. The company reported promising data from its CTx-1301 trial in July 2023, demonstrating a significant positive effect over placebo, which highlights the potential efficacy of its product offerings. These factors contribute to a positive outlook for Cingulate's stock by showcasing a strong market opportunity and the company's advancements in developing innovative therapeutic solutions.
Bears say
Cingulate Inc has reported a significant net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which exceeds both internal estimates and consensus expectations. Furthermore, the company's financial health is threatened by substantial liquidity risks, coupled with the uncertainty surrounding the safety and efficacy of its product candidates in ongoing clinical trials. The potential hurdles include regulatory approval challenges, commercialization difficulties, and adverse shifts in investor sentiment towards the biotech sector, all of which contribute to a detrimental outlook for the company's stock.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares